Given the implied value of just $3.41 per share (NASDAQ:DMTX) for the all-stock acquisition of Dimension Therapeutics Inc., Evercore ISI analyst Josh Schimmer asked Kenneth Mills, president and CEO of acquirer Regenxbio Inc., the question that likely was on everyone’s mind during a conference call to discuss the transaction. Could another suitor emerge with a competing bid?